Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$174.16M$174.16Mderived+6.0% vs Q4 2023 Net Income$15.33M$15.33Mderived+1,204.5% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$21,405,000N/M Operating Cash Flowderived$44,406,000−1.2% Free Cash Flowderived$44,193,000−1.8% Margins · derivedOperating margin12.3%+12.9 pt vs Q4 2023
Net margin8.8%+8.1 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 25, 2025 · 56 d after period end